Artiva Biotherapeutics Inc (NASDAQ: ARTV) saw its stock trade higher in premarket activity on Friday after releasing clinical data for its AlloNK therapy in refractory rheumatoid arthritis (RA) patients. Shares climbed roughly 6% as investors processed the company-reported results.
Clinical outcomes reported
Artiva said 71% of refractory RA patients reached an ACR50 response with at least six months of follow-up in company-sponsored Phase 2a basket-trial data. The company reported that, as of the data cutoff, no patients had relapsed or required initiation of new immunomodulatory agents.
The pooled clinical dataset comprised 21 refractory RA patients with a minimum of 12 weeks of follow-up, of whom 13 had reached six months of follow-up. These patients were drawn from Artiva's Phase 2a basket trial and an investigator-initiated trial. The treated cohort had a mean disease duration of 14.8 years, and 81% of patients had previously failed treatment with two or more biologic or targeted synthetic disease-modifying anti-rheumatic drug classes.
Safety and administration
Artiva described AlloNK's tolerability profile as supportive of outpatient administration in community rheumatology settings. The company reported no incidents of cytokine release syndrome, no cases of immune effector cell-associated neurotoxicity syndrome, and no treatment discontinuations in the data presented. In total, more than 70 autoimmune patients have been treated with AlloNK across more than 40 active clinical sites, the majority of which are community settings, according to the company.
Regulatory and development plan
The company said it has reached alignment with the U.S. Food and Drug Administration on a single Phase 3 registrational randomized controlled trial. The planned study will evaluate AlloNK in combination with rituximab versus rituximab alone in approximately 150 refractory RA patients. The primary endpoint for that trial will be the ACR50 response at six months, and Artiva expects the trial to begin in the second half of 2026.
Financing and balance sheet
Alongside the clinical update, Artiva announced the pricing of an underwritten offering that includes 23,871,526 shares of common stock at $11.52 per share and pre-funded warrants to purchase 2,170,138 shares. The company indicated gross proceeds from the offering are expected to be approximately $300 million before deducting underwriting discounts and commissions.
For the first quarter ended March 31, 2026, Artiva reported a net loss of $23.5 million, compared with a net loss of $20.3 million for the same period in 2025. As of March 31, 2026, the company reported cash, cash equivalents and investments totaling $86.8 million.
Market reaction and context
The immediate market response to the clinical announcement was positive in premarket trading, with the stock up around 6% as investors reacted to the reported ACR50 responses and the company’s stated plan for a registrational Phase 3 trial and concurrent financing. The clinical and financing updates together outline Artiva’s near-term development pathway and capital plans.
Takeaways
- Artiva reported that a majority of the refractory RA patients included in its presented dataset achieved an ACR50 response at six months, with no relapses or need for new immunomodulatory agents as of the cutoff.
- The company outlined a single Phase 3 registrational trial agreed with the FDA that is expected to start in the second half of 2026 and will enroll about 150 refractory RA patients.
- Artiva priced an underwritten equity offering expected to generate approximately $300 million in gross proceeds, and reported a first-quarter 2026 net loss of $23.5 million and cash, cash equivalents and investments of $86.8 million as of March 31, 2026.